VJCRGS issue celebrates ‘great lectures’ in ophthalmology
April 11th 2022Three prestigious lectures are featured, including Ehud Assia, MD, from Israel who gave the ESCRS Binkhorst Lecture; Richard Packard, MD, from England who gave the Choyce Lecture to the UKISCRS; and Michael Snyder, of the Cincinnati Eye Institute in Cincinnati, Ohio, USA, who delivered the Kelman Lecture at the 2021 American Academy of Ophthalmology meeting.
Read More
Intensive multimodal therapy is effective for orbital retinoblastoma
March 17th 2022Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.
Read More
Apellis announces longer-term data from Phase 3 DERBY and OAKS studies for geographic atrophy
March 16th 2022According to the company, pegcetacoplan demonstrated continuous and clinically meaningful effects at month 18 in the studies, which also found that treatment effects in DERBY were comparable to OAKS during months 6 to 18. The combined 18-month data show the potential for improving treatment effects over.
Read More
Ukrainian-born ophthalmologist staying positive for family remaining in war-torn country
March 16th 2022Anton Vlasov, DO, moved to the United States in 2001 at the age of 14, but since Russia invaded his homeland last month, the safety of family still living in Ukraine has weighed heavy on his mind.
Read More
Glaukos announces start of Phase II corneal health clinical program for pharmaceutical platform
March 14th 2022The company’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilize and reshape the cornea.
Read More